Understanding hippocampal excitatory and inhibitory circuits during perimenopause in alzheimer's disease mice

Active Grant Awarded Last action

Award ID
R01AG096604
Recipient
Awarding agency
Obligated
$696,253

Award facts

Assistance listing
93.866 Aging Research
Completion date 5% complete
Place of performance
North Chicago, IL 60064, USA

Award details come from USAspending.gov.

About this award

The National Institutes of Health's National Institute on Aging awarded Rosalind Franklin University of Medicine & Science $696,253 on August 28, 2026, under Assistance Listing 93.866, Aging Research. Award R01AG096604 funds research into how the perimenopause transition alters hippocampal excitatory and inhibitory circuits in Alzheimer's disease mice, with an ultimate completion date of May 31, 2031 and performance in North Chicago, Illinois. The study uses the chemical 4-vinylcyclohexene diepoxide to accelerate ovarian failure in mice, mimicking human menopause, and then measures behavior, hippocampal cell types, and neural activity in APPNLGF knock-in Alzheimer's model mice. Preliminary data from the investigators show increased anxiety-like behavior and weight gain in perimenopausal APPNLGF mice and decreased fear memory after menopause. The investigators also report decreased neuronal ensemble activation in the dorsal CA3 and increased parvalbumin-positive inhibitory activation in the ventral CA1. The working hypothesis holds that perimenopause disrupts ventral hippocampal activity and accelerates Alzheimer's neural and behavioral phenotypes. The Aging Research program supports biomedical, social, and behavioral research on the aging process and age-related diseases, with a particular emphasis on preventing and treating Alzheimer's disease and related dementias. The source identifies no sub-recipients for this award.

Description

Abstract
Ovarian hormones exert effects on brain regions like the hippocampus that modulate learning and memory. Fluctuations in these hormones during menopause transition (PERIMENOPAUSE) impact cognition and are linked to alzheimer's disease (ad) risk. For example, early surgical menopause in women increases dementia risk by 2-fold and results in more ad pathology. PERIMENOPAUSE and menopause transitions are an individualized experience yielding variations in symptomology depending on natural or surgical transition and age of onset. Some women report minimal cognitive decline while others have profound memory disturbances that are not reversed postmenopause. While there is a rich literature on the reproductive tract and aging, IT is still unknown how menopause transition alters brain-wide networks and increases ad risk. Here we aim to determine how menopause transition periods alter hippocampal cell types and neural activity and how these changes may accelerate ad pathology. To obtain a more complete picture of behavior and neuronal changes during the PERIMENOPAUSE transition we will mimic human menopause in mice using the chemical, 4-vinylcyclohexene diepoxide (VCD) to accelerate ovarian failure (AOF). Data collected in my lab revealed that appnlgf (knock-in ad model) mice in PERIMENOPAUSE exhibit increased anxiety-like behavior, and weight gain, and decreased fear memory in postmenopause compared to ad mice with typical hormone levels. Our prior work demonstrated that ad drives abnormal anxiety-like behaviors in females via the dorsal (DH) and ventral hippocampus (VH). IT is possible that PERIMENOPAUSE disrupts VH activity, accelerating ad neural and behavioral phenotypes. Specifically, we've observed decreased neuronal ensemble activation in the dorsal (DCA3) and increased parvalbumin (PV+) inhibitory activation in the ventral CA1 (VCA1) in female ad mice. IT is established that the VCA1 sends excitatory projections to the DCA3 which promotes spatial object recognition memory. Therefore, our conceptual framework is that PV+ inhibitory interneurons are increased in the VCA1 during PERIMENOPAUSE resulting in a decrease of excitatory activation in the DCA3 which will promote cognitive decline and ad pathology. In aim 1, we will use microscopy to determine VCA1 and DCA3 alterations in activated PV+ interneurons throughout menopause transition periods. In aim 2, we will measure neural activity in the DCA3 using miniscope technology and ablate specific hormone receptors to gain an understanding of how menopause transitions and hormones impact neural activity. Lastly, in aim 3 we will chronically chemogenetically manipulate the VCA1ÀDCA3 circuit in an attempt to restore E/I imbalance throughout menopause transitions.

Transactions

Action Obligated Date
Amendment $0
Original award $696,253

Quick answers

Who received award R01AG096604?

R01AG096604 was awarded to Rosalind Franklin University Of Medicine & Science by National Institute on Aging (National Institutes of Health) on August 28, 2026.

How much is award R01AG096604 worth?

$696,253 has been obligated on R01AG096604.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award